716
Background:
Real-world evidence can help evaluate whether advances in oncology care are being consistently translated into routine clinical practice. The rapid evolution of immunotherapy and targeted therapies has reshaped the management of metastatic non-small cell lung cancer (mNSCLC). However, the extent...
Á. Rogado, Rocio Casado, C. Camps et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...
H. Wakelee, J. Spicer, S. Gao et al.· Annals of Oncology· 1 citation
INTRODUCTION
For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. However, real-world data describing tre...
D. Owen, Martin Sebastian, H. Kenmotsu et al.· Oncology and Therapy· 0 citations
This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.